India Urged to Accelerate Pandemic Preparedness: NITI Aayog's Dr. V.K. Paul Calls for Immediate Action on High-Risk Pathogens

Spread the Message

Read Time:4 Minute, 13 Second

On January 24, 2026, at the 42nd Foundation Day of CSIR-Institute of Microbial Technology (IMTECH) in Chandigarh, NITI Aayog member Dr. V.K. Paul delivered a stark warning: preparations for future pandemics must begin now, not during crises. Speaking to scientists, he outlined a roadmap emphasizing research on priority pathogens, robust surveillance, and rapid countermeasures deployable within the first 100 days of an outbreak. This comes amid global concerns over rising infectious threats, positioning India to lead in proactive health security.

Key Developments from Dr. Paul’s Address

Dr. Paul, who heads NITI Aayog’s health, nutrition, and education verticals, stressed four pillars for pandemic strategy: governance, surveillance, research, and partnerships. He urged IMTECH—a national hub for microbial sciences established in 1984—to prioritize high-risk pathogens with pandemic potential, advancing countermeasures to Phase II clinical trials in collaboration with industry. Efficient supply chains and demonstrated rapid response capabilities are essential, he noted, drawing from India’s COVID-19 experience where science-driven actions contained the virus.

IMTECH’s pandemic role was highlighted, including RT-PCR testing, a subunit protein-based COVID-19 vaccine candidate, and antiviral screenings against SARS-CoV-2. Dr. Paul praised these as evidence-based successes involving government, society, and stakeholders. Ongoing IMTECH projects on antimicrobial resistance (AMR), bioremediation, and neurodegenerative diseases further underscore its translational focus.

Expert Commentary and Perspectives

Dr. Sanjeev Khosla, Director of CSIR-IMTECH, echoed the urgency, stating, “Innovating with microbes and impacting lives has been the guiding force for the scientists and researchers of the IMTECH family over the last four decades.” He positioned the institute’s vision as propelling India forward through microbial innovation.

Independent experts align with this proactive stance. “Research must not be confined to laboratories; it should inform policy, guide early-warning systems, and support rapid response mechanisms,” Dr. Paul emphasized, advocating interdisciplinary ties with virologists and epidemiologists. Analysts note this shifts India toward anticipatory science, potentially making it a pathogen research leader, though translating lab work into diagnostics and vaccines remains challenging.

From a global lens, WHO’s Pandemic Agreement, adopted in May 2025, reinforces such efforts by strengthening prevention via the International Health Regulations and surge financing for developing nations like India.

Background and India’s Evolving Strategy

India’s pandemic response has evolved post-COVID. NITI Aayog’s 2024 Expert Group report on Future Pandemic Preparedness identifies gaps like fragmented surveillance, unlinked research-industry chains, and legislative shortcomings in the Epidemic Diseases Act. It pushes a “One Health” approach integrating human, animal, and environmental health to combat zoonotics—responsible for 75% of emerging diseases.

Initiatives include the Preparedness and Resilience for Emerging Threats (PRET) blueprint for respiratory pathogens, INSACOG genomic network (now with 38 labs sequencing over 10,000 samples monthly pre-COVID), and digital tools like Aarogya Setu. The Pradhan Mantri-Ayushman Bharat Health Infrastructure Mission bolsters labs and oxygen plants. Yet, challenges persist: no real-time national data dashboard and under-resourced systems strained by ongoing issues like TB.

IMTECH exemplifies progress, completing 24 industry projects during COVID generating economic value while aiding UVC air disinfection and anti-TB compounds.

Public Health Implications

For India’s 1.4 billion people, this means faster outbreak detection via genomic surveillance and AI modeling, reducing mortality like COVID’s 530,000 deaths. Everyday implications include stockpiled PPE (India produced 4.5 lakh/day at peak), telemedicine scaling, and community risk communication to avoid panic.

A 100-day action plan—track, test, treat, isolate—could prevent healthcare collapse, ensuring non-COVID care like cancer treatment continues. Globally, India’s vaccine diplomacy (COVAX supplied 240 million doses) positions it as a supplier, but domestic manufacturing must surge for equity.

Limitations and Counterarguments

While optimistic, gaps loom. Experts warn of political will deficits for open data ecosystems and regulatory reforms for swift approvals. AMR and climate-driven diseases add complexity; neglected infections could spark tomorrow’s pandemics. Funding shortages hinder One Health scaling across ministries.

Davos 2026 discussions flagged global unreadiness, with slowed momentum post-COVID. India’s framework addresses this but requires execution; the 2024 NITI report notes COVID silos displaced routine care. Diverse viewpoints stress whole-of-society buy-in over top-down mandates.

Path Forward for India

Dr. Paul’s roadmap aligns with NITI’s vision: preemptive pathogen work in labs like IMTECH to build resilient systems. Success hinges on public-private partnerships, skilling 2.5 million health workers, and international collaboration. As threats rise—WHO notes increasing high-threat hazards—India’s actions today safeguard tomorrow.

This event signals momentum, but sustained investment is key to turning rhetoric into reality.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.